Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Heart Matters

No benefit of routine spironolactone post-MI

Sanjit Jolly at AHA
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    AHA 2024 - Sanjit Jolly shares the spironolactone factorial results of the CLEAR SYNERGY (OASIS 9) trial, in which routine use of spironolactone did not reduce the risk of the two co-primary endpoints after an MI.

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.

  • Faculty

    Sanjit Jolly, MD is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University in Hamilton, ON, Canada. 

  • Disclaimer

Recommended
Details
Presenters
Comments
  • Overview

    AHA 2024 - Sanjit Jolly shares the spironolactone factorial results of the CLEAR SYNERGY (OASIS 9) trial, in which routine use of spironolactone did not reduce the risk of the two co-primary endpoints after an MI.

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.

  • Faculty

    Sanjit Jolly, MD is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University in Hamilton, ON, Canada. 

  • Disclaimer

Schedule9 Dec 2024